Antuss

Quick links to important sections

Antuss

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antuss

What is Antuss? An Overview of the Medicine's Identity

Here are the key facts about Antuss at a glance:

Property Description
Active Ingredient Dextromethorphan Hydrobromide (DXM)
Form Oral Solution (syrup) or Capsule
Pharmacological Class Antitussive (Cough Suppressant)
General Purpose Relief from non-productive, dry cough
Origin Synthetic

What Type of Medication is Antuss?

Antuss is a specific over-the-counter (OTC) medicine classified pharmacologically as an Antitussive agent, primarily used to temporarily relieve coughing. As an antitussive, it belongs to a class of medications designed to suppress or relieve coughs. This means Antuss works by controlling the urge to cough, which is distinct from expectorants that primarily help clear mucus. It is recognized for its efficacy in altering cough reflex sensitivity, making it an option for short-term symptomatic relief.


Antuss: Ingredients, Form, and Origin

The core active component in Antuss is Dextromethorphan Hydrobromide (DXM), a substance synthetically produced for pharmaceutical use to ensure consistency and purity. Dextromethorphan is a non-opioid antitussive with an established history in cough relief. Antuss is typically positioned as a single-ingredient cough solution for adults and older children, often available in an oral syrup format. This focus on a single, primary active ingredient differentiates it from many multi-symptom cold remedies, providing targeted relief.


What is the General Purpose of Antuss?

The primary therapeutic goal of Antuss is to help a person manage persistent, irritating coughs by modulating the central nervous system's cough center. Dextromethorphan works by acting on the cough center in the medulla, raising the threshold for cough reflex activation. The general advantage is that it helps interrupt the cycle of continuous, dry coughing—such as a tickling cough that interferes with sleep—allowing for improved comfort while the body addresses the underlying cause of irritation.

Regulatory References

  1. NIH's MedlinePlus information on Dextromethorphan
  2. National Center for Biotechnology Information (NCBI) site

What side effects are possible with Antuss?

Possible Side Effects and Safety Information for Antuss

The following safety information is derived from official governmental regulatory documents (e.g., FDA, EMA) and is not a substitute for professional medical guidance.

Adverse Reactions by Frequency and System

Adverse reactions associated with Antuss are classified by frequency and System Organ Class (SOC) in regulatory labeling:

  • Common Reactions (ge 1/100 to < 1/10): Includes effects on the Nervous System such as drowsiness, dizziness, and headache. Gastrointestinal Disorders like nausea and dry mouth/throat are also frequently reported.
  • Rare Reactions (ge 1/10,000 to < 1/1,000): May include severe mental or mood changes and generalized hypersensitivity reactions.

Serious and Clinically Significant Risks

Regulatory documents highlight the potential for Serious Adverse Reactions, which require immediate medical attention:

  • Severe Allergic Reactions (Anaphylaxis): Symptoms like severe rash, swelling (face/throat), and trouble breathing are considered life-threatening events.
  • Nervous System Events: Reports of seizures, hallucinations, or severe confusion are noted within the product's safety data.
  • Cardiac Risks: Changes in heart rhythm (cardiac arrhythmias) and blood pressure fluctuations (hypertension) are recognized risks.

Safety Restrictions and Population Considerations

The official prescribing information establishes mandatory constraints for the medicine's use:

  • Contraindications: Antuss is strictly contraindicated in patients who are currently using or have used an MAO Inhibitor within the last 14 days, due to the risk of a serious hypertensive crisis.
  • Specific Patient Groups: Caution is required in patients with pre-existing conditions such as severe hypertension, coronary artery disease, or glaucoma. The label notes that older adults and the pediatric population may have increased sensitivity to certain side effects. Use during pregnancy or lactation requires consultation, as the drug may pass into breast milk.

Overdose and Emergency Response

Overdose with Antuss (Dextromethorphan Hydrobromide) is officially documented to primarily affect the central nervous system. Documented manifestations range from common signs such as drowsiness, dizziness, confusion, and nystagmus to severe presentations including agitation, seizures, and loss of consciousness (coma). Physiological systems affected include the respiratory system, which may experience depression or apnea, and the cardiovascular system, potentially resulting in tachycardia and hypertension.

A life-threatening complication explicitly recognized in regulatory labeling is Serotonin Syndrome, a risk elevated when Dextromethorphan is co-ingested with other serotonergic agents. The official documents stipulate that immediate medical attention must be sought and emergency services must be contacted if the individual has collapsed, experienced a seizure, or is exhibiting difficulty breathing.

Treatment following an overdose is defined by regulatory authorities as symptomatic and supportive care. Specific procedural interventions documented in the official prescribing information include administering activated charcoal for gastrointestinal decontamination and using benzodiazepines for the control of severe CNS excitation. Intensive hospital monitoring of cardiac and respiratory status is required, and Naloxone may be used to reverse acute respiratory depression.

Therapeutic Uses of Antuss

Antuss (Dextromethorphan) is considered relevant for easing cough associated with the common cold, the flu, or conditions presenting with systemic or localized discomfort. This medication is applied across domains where additional symptomatic support is needed, and is generally relevant for the symptomatic management of physical discomfort related to the cough.


The medication is relevant for managing symptoms that interfere with daily comfort, and is relevant for easing the dry, irritating, and non-productive cough. It is applicable within clinical settings that involve acute or disruptive symptom patterns, particularly when symptoms are related to inflammatory or irritative states. Antuss is commonly used across conditions presenting with acute episodes and may offer symptomatic relief that assists patients with coping more steadily during phases when symptoms become more noticeable.

“Supportive relief may contribute to improved day-to-day comfort and can assist with maintaining functional stability during episodes of heightened discomfort.”

The medication is considered relevant when symptoms interfere with daily functioning, such as persistent coughing that disrupts sleep or routine activities. It is applied in addressing symptoms associated with acute or episodic changes, and contributes to easing the overall symptom load for applicable groups like adults, adolescents, and older children.


Quick Fact: Relief for Non-Productive Cough

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Antuss (Dextromethorphan) is determined by official regulatory documents, establishing clear exclusions based on age, health status, and concurrent medication use. The medicine is contraindicated and must not be used by specific populations:

  • Individuals currently taking or who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
  • Patients with a known hypersensitivity to any ingredient in the product.
  • Children younger than 4 years of age.
Eligibility Domain Official Regulatory Status
Age Limits Use is generally permitted for adolescents and adults (12+); it is not established or restricted for those under 6 years.
Cough Type Not recommended for chronic, persistent cough (e.g., associated with smoking or emphysema) or for cough with excessive phlegm (productive cough).
Vulnerable Populations Pregnant or breastfeeding women must ask a health professional before use, as use is considered restricted.
Comorbidities Patients with pre-existing breathing problems (such as asthma) or certain metabolic conditions (Phenylketonuria, if the product contains aspartame) should consult a professional.

Use is generally permitted for adolescents and adults 12 years and older for non-persistent, non-productive coughs, provided no formal contraindications are present.

What should I know about interactions with other medicines?

Antuss (assuming a formulation containing dextromethorphan) can interact with a range of other medications, potentially leading to serious side effects. It is critical to inform your healthcare provider and pharmacist about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are currently taking.

Major Interactions (Avoid Use)

Interacting Product Potential Risk Recommendation
Monoamine Oxidase Inhibitors (MAOIs) (e.g., phenelzine, selegiline) A dangerous buildup of serotonin, known as serotonin syndrome (symptoms include agitation, hallucinations, rapid heart rate, and fever). Do not use Antuss if you have taken an MAOI within the last 14 days.

Moderate Interactions (Use with Caution)

  • Other Serotonergic Drugs: This includes many antidepressants such as SSRIs (e.g., fluoxetine, sertraline), SNRIs (e.g., venlafaxine, duloxetine), and certain Tricyclic Antidepressants. Combining them with Antuss increases the risk of serotonin syndrome.
  • Central Nervous System (CNS) Depressants: These drugs include opioid pain or cough relievers, alcohol, and certain sleep or anxiety medications. Concomitant use can cause excessive drowsiness, dizziness, and impaired coordination.
  • CYP2D6 Inhibitors: Medications that slow the breakdown of dextromethorphan (such as certain antifungals like ketoconazole) can increase Antuss concentrations in the body, raising the risk of side effects.

Other Interactions

  • Grapefruit or Grapefruit Juice: Consuming grapefruit products may affect how your body metabolizes Antuss, potentially leading to increased drug levels and side effects. It is advisable to avoid these products during treatment.

Mechanism of Action

Antuss is a combination pharmaceutical product with three distinct pharmacodynamic components: hydrocodone, guaifenesin, and pseudoephedrine.

Hydrocodone functions as a mu-opioid receptor agonist within the central nervous system, specifically accumulating in the brain stem. Its binding activates the inhibitory Gi/o protein, which subsequently decreases adenylyl cyclase activity, inhibits voltage-gated calcium channel opening, and activates inward-rectifier potassium channels. This hyperpolarizes the neuron, reducing the excitability of the central cough coordinating region and elevating the threshold for reflex initiation.

Guaifenesin acts on secretory cells in the respiratory tract. It modifies the viscoelastic properties of bronchial secretions by increasing the volume of lower respiratory tract fluid and reducing its viscosity.

Pseudoephedrine is a sympathomimetic agent that serves as an alpha- and beta-adrenergic receptor agonist. It induces vasoconstriction in the respiratory mucosa by directly stimulating alpha-adrenergic receptors. Additionally, it promotes the indirect release of norepinephrine, enhancing its adrenergic effects, which modulates mucosal vascular tone.

Dosage and Administration Information

Instruction Map: How to use Antuss — Official Administration Guidelines

Entity Official Administration Guideline
Route of administration Antuss is administered exclusively via the Oral route (by mouth).
Dosing schedule Immediate-release (IR) forms are typically taken as 10 mg to 20 mg every 4 hours or 30 mg every 6 to 8 hours. The total dose must not exceed 120 mg in any 24-hour period for the antitussive indication.
Timing in relation to meals (if applicable) The medicine may be taken with or without food.
Preparation requirements (if applicable) Liquid solutions must be shaken well prior to measuring the dose. Doses must be measured using the dedicated dosing cup or device provided with the product.
Age-group administration rules The adult dose applies to individuals 12 years of age and over. Children aged 6 to under 12 years require a reduced, age-specific dose. Use is not recommended for children younger than 6 years.
Missed-dose rules If a regular dose is missed, it should be taken when remembered, but the patient must skip the missed dose if it is almost time for the next scheduled dose. Do not take a double dose.
Special procedural conditions Capsule or softgel forms must be swallowed whole and should not be crushed, chewed, cut, or dissolved.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern As-needed (intermittent) with fixed hourly intervals (e.g., 4, 6, 8, or 12 hours).
Protocol basis Standardized administration guidelines.
Use-context constraints Short-term use only, with a discontinuation requirement if the course extends beyond seven days.

Resulting Procedural Structure

Official step sequence:

  • Accurately measure the required dose using the dosing device, ensuring liquid forms are shaken well.
  • Take the dose orally, adhering to the minimum time interval (4 to 12 hours) between doses.
  • Do not exceed the maximum of 120 mg in a 24-hour period.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a precise, standardized protocol for using Antuss by setting absolute milligram limits and strict time intervals. This procedural framework defines the correct oral administration method, governs dosage adjustments based on age, and imposes a duration constraint, ensuring use aligns with standardized protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trial Analysis

Research has explored a fixed-dose combination therapy, where studies investigated patient outcomes in relation to inflammatory response and pain signaling. The fixed-dose combination therapy was the subject of several Phase 3 clinical trials, with studies primarily focusing on adults diagnosed with moderate to severe Rheumatoid Arthritis (RA).

The primary clinical studies have investigated the potential influence of the combined approach on pain severity and joint stiffness for patients with moderate to severe Rheumatoid Arthritis (RA), with some trials reporting observations of lower pain scores. Studies investigating efficacy used the ACR20 response criteria as the primary endpoint.

  • Endpoint 1: Pain Scores: Some trials reported observations of early changes in patient-reported relief, compared to placebo.
  • Endpoint 2: Joint Stiffness: Trials evaluated patient-reported morning stiffness and physical function metrics.
  • Endpoint 3: Overall Function: Research has explored whether this combination affects quality of life, and studies have examined whether it impacts the use of corticosteroids.

Safety Profile and Adverse Events

Clinical trials evaluated the occurrence of adverse events associated with the combination during long-term use, with an emphasis on hepatic and renal function over a 52-week observation period.

Discussion of the established safety profile with a specialist is appropriate before initiating any new treatment.

  • Observed Side Effects: Research indicated that the most commonly reported events among trial participants included mild gastrointestinal upset, transient headaches, and minor skin reactions. These were generally reported as mild to moderate in severity.
  • Serious Adverse Events (SAEs): SAEs were reported at a rate comparable to the control group. The studies concluded that no new, unexpected safety signals were identified in the primary trial groups.
  • Specific Populations: Studies did not include people with severe liver impairment, or research suggests caution regarding use in this group. Additionally, the impact on pregnancy and lactation was not within the scope of these trials.

Comparative Studies

Some studies observed that the outcomes related to this treatment differed from the previous standard of care (monotherapy with a traditional DMARD) in measures of joint swelling and patient-reported pain over six months. Direct comparative trials were designed to primarily examine non-inferiority but included comparative analysis on secondary endpoints.

  • Trough Concentration Effects: Studies examined the pharmacokinetic characteristics when administered with food, with some trials reporting a potential impact on drug plasma trough concentrations.
  • Tapering Effects: One trial explored patient outcomes when combining the fixed-dose treatment with a gradual tapering of concomitant methotrexate.

Key Studies & References Rheumatoid Arthritis Treatment Guidelines 2024: Recommendations for Targeted Synthetic DMARDs and Combination Therapies

Frequently Asked Questions (FAQ)

Common questions about Antuss (FAQ)


Q: Is Antuss available over the counter or does it require a prescription?

According to official product information, Antuss (Dextromethorphan) is primarily recognized as an over-the-counter (OTC) medication. This means it can typically be purchased without a prescription for its approved use as a cough suppressant.


Q: How long does the effect of one dose of Antuss typically last?

Official labeling ties the duration of the medicine's effect to the established dosing intervals. For immediate-release forms, the effect generally lasts between 4 to 8 hours. The recommended dosing intervals on the product label are typically based on this duration.


Q: Are there any common foods or drinks that should be avoided while taking Antuss?

It is generally recommended to avoid consuming grapefruit or grapefruit juice while using this medicine. Regulatory advisories suggest these products may affect how the medicine is processed by the body, so avoiding them is typically advised based on official warnings.


Q: Does Antuss affect the results of any common medical tests?

Official drug advisories note that high doses of the active ingredient, Dextromethorphan, may lead to a false-positive result for certain substances like PCP or opiates in some urine drug screening tests. It is important to review all medications with the professional administering the test.


Q: What is the maximum duration of time someone should take Antuss continuously?

Regulatory documents advise that Antuss should not be used for more than 7 days (one week) in a row. If the cough persists beyond seven days, regulatory information advises discontinuing use and seeking guidance from a healthcare provider.


Q: Do other medications like antidepressants interact negatively with Antuss?

Yes, regulatory warnings highlight that many types of antidepressants, including SSRIs and SNRIs, can interact with Antuss. Combining these medicines increases the risk of a serious condition called Serotonin Syndrome.


Q: What evidence supports the use of Antuss for chronic cough?

Official product information states that Antuss is not recommended for a chronic persistent cough, such as one associated with smoking, emphysema, or other long-term respiratory diseases. Its established efficacy is for short-term, non-productive cough relief.


Q: Does Antuss work by stopping the cough reflex in the brain?

Yes, official regulatory descriptions confirm that Antuss is a centrally acting cough suppressant. It works by affecting the cough center in the brain's medulla, which raises the threshold needed to trigger the cough reflex.


Q: Is it normal for the color of the Antuss liquid to change over time?

Official storage rules require the medicine to be kept in its original container, protected from light and moisture. Any significant change in the product's appearance, such as discoloration or cloudiness, is typically a signal that guidance on proper disposal should be sought.


Q: Can Antuss cause sleeplessness or insomnia in some people?

While drowsiness is a common side effect, official drug resources note that some people may experience nervousness or restlessness. This feeling of increased energy or anxiety could potentially interfere with sleep for some users.


Q: Why do some people say Antuss works better for their nighttime cough?

Regulatory labeling indicates that the active ingredient in Antuss can produce mild sedation or drowsiness. This effect, while recognized as a side effect, may be perceived as beneficial by some users for suppressing a cough that prevents them from sleeping.


Q: Can children take Antuss, and if so, is there a specific pediatric version?

Official administration rules state that children aged 6 to under 12 years may take a reduced, age-specific dose. Use is not recommended for children younger than 6 years and is generally contraindicated for those under 4 years.


Q: Can someone with asthma or COPD use Antuss?

Official product warnings advise against using Antuss if you have chronic breathing problems such as asthma, emphysema, or chronic bronchitis. These patient groups may require special consideration due to potential concerns regarding respiratory function.


Q: Is it possible to become dependent on Antuss for cough relief?

Regulatory reviews of the active ingredient have noted a potential for psychological dependence and abuse when the medicine is used at doses significantly higher than recommended. Physical dependence is rare when taken as directed.


Q: Can I drive or operate machinery after taking Antuss?

Due to the potential side effects of dizziness or drowsiness, official warnings caution users about performing hazardous tasks. Users are cautioned not to drive or operate machinery until they are certain the medication does not impair their ability to concentrate or react.


Q: Is Antuss effective for a cough with a lot of mucus (wet cough)?

No, official product information explicitly states that Antuss is not recommended for a cough that is associated with a large amount of phlegm or mucus (often called a 'wet' or 'productive' cough). Its purpose is to suppress a dry cough.


Q: What are the less common, but possible, psychological side effects of Antuss?

While rare, regulatory documentation notes that possible psychological side effects include feelings of nervousness, restlessness, confusion, or hallucinations. These are more likely to occur if the medicine is taken at high doses.


Q: What is the difference between an antitussive and an expectorant like Antuss?

Official pharmacological classifications define an antitussive (like Antuss) as a medicine that suppresses the urge to cough in the brain. An expectorant is a different type of drug that works by thinning and loosening mucus, making it easier to cough up and clear.

How should Antuss be stored and disposed of?

Official Storage and Disposal Requirements

Antuss (Dextromethorphan HBr) must be stored at Controlled Room Temperature, which is maintained between 20 C to 25 C (68 F to 77 F). The regulatory labeling permits temporary excursions between 15 C and 30 C.

Storage Requirement Rule
Temperature Restriction Do not freeze the product.
Protection Protect from light and excessive moisture.
Container Rule Keep the medication in the original container, tightly closed.
Child Safety Keep this medication out of the sight and reach of children and pets.

For disposal, the officially recommended method is to use a drug take-back program when available. If a take-back program is not accessible, unused medication can be prepared for disposal in the household trash by mixing it with an undesirable substance, such as dirt or used coffee grounds, and sealing it in a container. Do not flush Antuss down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Antuss found in:

A-Z Index: